What You'll Learn: Mapping the Next Frontier of Growth: How Southern California’s biotech, pharma, therapeutics and medtech industries are evolving, and which markets are maturing fastest. Commercial Real Estate Outlook: How landlords, developers and owners are adapting to laboratory and biomanufacturing requirements in a rapidly advancing industry. Funding & Investment Conditions: Who is investing, what...
Despite nearly two decades of industry surveys demonstrating a steady demand for new and improved single-use technologies, next-generation films, polymers, and components struggle to achieve widespread adoption. Join Bioprocess Online’s Tyler Menichiello for an interactive panel discussion examining how regulatory lag, evolving biocompatibility standards, and the complexity of converting legacy systems slow the uptake of...
Modern screening approaches generate rich datasets that capture how large collections of compounds interact with biological targets. However, discovery teams often rely on only a small portion of that information when selecting compounds for synthesis, potentially missing important signals across the broader dataset. In this webinar, we explore how evaluating the full screening landscape can...
As clinical trials become increasingly outsourced, a critical gap has emerged between sponsor expectations and CRO execution. Many smaller biotech companies rely heavily on outsourcing vendors to drive their programs, often without the internal clinical operations infrastructure needed to provide direction, oversight, and strategic alignment. At the same time, vendor teams—particularly CRAs—are frequently stretched thin...
Research findings from 150 manufacturing leaders uncovered a "connectivity crisis" preventing production optimization. This webinar addresses the imperative to break down the silos today that are creating the delays, rework, and compliance issues that 90%-plus manufacturers struggle with. Start at the bottom and build the connected data foundation that makes AI actually work.
In this session, explore how digitally connected execution ecosystems move manufacturers from reactive response to proactive control, enabling faster decisions, fewer errors, and inspection-ready operations by design.
Radiopharmaceuticals and radioligand therapies were involved in multibillion dollar M&A transactions over the last several years. Panelists on this Life Science Leader virtual event will discuss emerging technologies and radioisotopes, what new market opportunities exist, and what manufacturing and delivery challenges remain for radiopharmaceutical developers. Registered attendees will have the opportunity to pose their own...
Discover how precision genome editing is advancing the next generation of genetic medicines. Learn strategies to achieve highly specific, potent DNA edits while minimizing off-target effects and meeting rigorous safety standards for clinical translation. What you’ll learn: - How to precisely correct disease mutations without creating unwanted edits - Engineering and optimizing DNA recognition to...
Kickoff the America250 celebrations with the fifth annual Life Sciences PA Tailgate! Join us April 30, 2026 in the heart of Philadelphia and at life sciences hub, The Lawn @uCity Square, for food trucks, games, live music, and networking with other life sciences professionals. Register as an individual to enjoy the fun of the tailgate atmosphere without any setup,...
We are very excited to announce our outdoor Ventura BioCenter Life Science Community Event in Thousand Oaks! Mark your calendars for a great opportunity to connect with industry leaders, explore innovative products, and mingle with fellow professionals in the biotech community. ✨ What to Expect: Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge...
A practical look at overcoming viscosity, fouling, and aggregation with modern TFF platforms. As monoclonal antibody therapies continue to evolve, the industry is rapidly shifting from traditional mAb formulations to high‑concentration mAbs to enable subcutaneous delivery, improve patient convenience, and support next‑generation therapeutics. While this shift delivers clear clinical benefits, it also introduces new risks...
Selective gene delivery to defined cell populations using targeted lentiviral vectors (LVV) represents a promising strategy for next‑generation immunotherapies such as chimeric antigen receptor (CAR) T‑cell therapy. While conventional CAR-T cell manufacturing requires multiple ex vivo manipulation steps up to two weeks, targeted LVVs can enable a short ex vivo manufacturing process or direct in...
